Introgen Therapeutics Reports Third Quarter 2008 Financial Results (Centre Daily Times)
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced financial results for the quarter and nine months ended September 30, 2008, and highlighted recent corporate developments.

Testosterone Effective in Female Sexual Dysfunction; BioSante Conducting Long-Term Safety Study of LibiGel(R) in FSD (Centre Daily Times)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male hypogonadism, commented today on a new publication reporting on the efficacy of testosterone in the treatment of Female Sexual Dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD) in menopausal women. In ...

Orasure Technologies Files For FDA Approval Of Oraquick Rapid Hepatitis C Test (PharmaceuticalOnline)
OraSure Technologies, Inc. recently announced that it has submitted a pre-market approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for a rapid test for antibodies to the Hepatitis C virus ("HCV") utilizing OraSure Technologies' OraQuick technology platform.